Berkshire Hathaway reveals $4.3 billion stake in Alphabet, cuts Apple
Director Alexander M. Gold of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) recently sold 35,675 shares of common stock for a total of $1,576,094. The sales, which occurred on November 11th, 12th and 13th, were executed in a price range of $42.4298 to $47.2766 per share.
On the same dates, Gold exercised options to acquire a total of 34,675 shares of Mineralys Therapeutics stock at prices ranging from $10.20 to $12.69, for a total value of $378,585.
In other recent news, Mineralys Therapeutics Inc. reported a narrower-than-expected loss for the third quarter of 2025. The company’s earnings per share (EPS) were -$0.52, significantly better than the forecasted -$0.96. This performance was accompanied by promising updates on their lead drug, Lorandirostat. These developments have generated positive reactions from investors, as indicated by the strong market response. The company’s ability to exceed EPS expectations is noteworthy for stakeholders monitoring its financial health. While the stock price movement is not the focus here, the earnings report provides valuable insights into the company’s current status. Investors and analysts will likely continue to watch Mineralys Therapeutics closely following these recent announcements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.